High Dietary Taurine Reduces Apoptosis and Atherosclerosis in the Left Main Coronary Artery Association With Reduced CCAAT/Enhancer Binding Protein Homologous Protein and Total Plasma Homocysteine but not Lipidemia

Hypertension

Volumn 53, Issue 6, 2009, Pages 1017-1022

  Zulli, Anthony ^a,c   Lau, Eza ^a   Wijaya, Bagus P P ^a   Jin, Xin ^a   Sutarga, Komang ^a   Schwartz, Grace D ^a   Learmont, Jonathon ^a   Wookey, Peter J ^a   Zinellu, Angelo ^a,b   Carru, Ciriaco ^b   Hare, David L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SASSARI   (Italy)

^c AUSTIN HEALTH   (Australia)

Author keywords

Atherosclerosis; Cholesterol; CHOP; Homocysteine; Methionine; Plaque

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; METHIONINE; TAURINE; CCAAT BINDING FACTOR; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DIET SUPPLEMENTATION; ENDOTHELIUM CELL; EXPERIMENTAL RABBIT; HYPERHOMOCYSTEINEMIA; LEFT CORONARY ARTERY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; ATHEROGENIC DIET; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG EFFECT; HYPERLIPIDEMIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROBABILITY; RABBIT; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CCAAT-BINDING FACTOR; CORONARY ARTERY DISEASE; DIET, ATHEROGENIC; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HYPERLIPIDEMIAS; MALE; METHIONINE; NITRIC OXIDE; OXIDATIVE STRESS; PROBABILITY; RABBITS; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TAURINE;

EID: 67049158000     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.129924     Document Type: Article

References (51)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I-general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
2. World Health Organization. Global Burden of Disease: 2004 Update. 2008. Geneva, Switzerland: WHO Press; 2008.
3. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
4. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885-1899.
5. Nittynen L, Nurminen ML, Korpela R, Vapaatalo H. Role of arginine, taurine and homocysteine in cardiovascular diseases. Ann Med. 1999;31: 318-326.
6. Yamori Y, Nara Y, Ikeda K, Mizushima S. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv Exp Med Biol. 1996;403:623-629.
7. Nandhini AT, Thirunavukkarasu V, Ravichandran MK, Anuradha CV. Effect of taurine on biomarkers of oxidative stress in tissues of fructose-fed insulin-resistant rats. Singapore Med J. 2005;46:82-87.
8. Tsuboyama-Kasaoka N, Shozawa C, Sano K, Kamei Y, Kasaoka S, Hosokawa Y, Ezaki O. Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity. Endocrinology. 2006;147: 3276-3284.
9. Zulli A, Hare DL, Buxton BF, Black MJ. High dietary methionine plus cholesterol exacerbates atherosclerosis formation in the left main coronary artery of rabbits. Atherosclerosis. 2004;176:83-89.
10. Zulli A, Widdop RE, Hare DL, Buxton BF, Black MJ. High methionine and cholesterol diet abolishes endothelial relaxation. Arterioscler Thromb Vasc Biol. 2003;23:1358-1363.
11. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
12. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6:830-838.
13. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369:1876-1882.
14. Martin-Venegas R, Rodriguez-Lagunas MJ, Mercier Y, Geraert PA, Ferrer R. Effect of pH on L- and D-methionine uptake across the apical membrane of Caco-2 cells. Am J Physiol Cell Physiol. 2009;296: C632-C638.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
17. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993;290:165-172.
18. Panzenboeck U, Raitmayer S, Reicher H, Lindner H, Glatter O, Malle E, Sattler W. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 1997;272:29711-29720.
19. Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem. 2002;277:32172-32179.
20. Abebe W. Effects of taurine on the reactivity of aortas from diabetic rats. Life Sci. 2008;82:279-289.
21. Tan B, Jiang DJ, Huang H, Jia SJ, Jiang JL, Hu CP, Li YJ. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol. 2007;46:338-345.
22. Abebe W, Mozaffari MS. Taurine depletion alters vascular reactivity in rats. Can J Physiol Pharmacol. 2003;81:903-909.
23. Abebe W, Mozaffari MS. Effects of chronic taurine treatment on reactivity of the rat aorta. Amino Acids. 2000;19:615-623.
24. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000;18:305-318.
25. Azuma M, Takahashi K, Fukuda T, Ohyabu Y, Yamamoto I, Kim S, Iwao H, Schaffer SW, Azuma J. Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur J Pharmacol. 2000;403:181-188.
26. Li C, Cao L, Zeng Q, Liu X, Zhang Y, Dai T, Hu D, Huang K, Wang Y, Wang X, Li D, Chen Z, Zhang J, Li Y, Sharma R. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. Cardiovasc Drugs Ther. 2005; 19:105-112.
27. Wang J, Peng YJ, Zhu DN. Amino acids modulate the hypotensive effect of angiotensin-(l-7) at the caudal ventrolateral medulla in rats. Regul Pept. 2005;129:1-7.
28. Olszanecki R, Marcinkiewicz J. Taurine chloramine and taurine bro-mamine induce heme oxygenase-1 in resting and LPS-stimulated J774.2 macrophages. Amino Acids. 2004;27:29-35.
29. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
30. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354-1363.
31. Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani R. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269-272.
32. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-891.
33. Vissers MC, Pullar JM, Hampton MB. Hypochlorous acid causes caspase activation and apoptosis or growth arrest in human endothelial cells. Biochem J. 1999;344:443-449.
34. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691-728.
35. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes. 2002;51:198-203.
36. Casey RG, Gang C, Joyce M, Bouchier-Hayes DJ. Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte-en-dothelial cell interactions and cardiac dysfunction. J Vasc Res. 2007;44: 31-39.
37. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol. 1999;277:C1229-C1238.
38. Ulrich-Merzenich G, Zeitler H, Vetter H, Bhonde RR. Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr. 2007;46:431-438.
39. Nonaka H, Tsujino T, Watari Y, Emoto N, Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation. 2001;104:1165-1170.
40. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
41. Schuller-Levis GB, Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res. 2004;29:117-126.
42. Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM, Jacobs DR Jr. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2006; 83:1369-1379.
43. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, Austin RC. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood. 1999;94:959-967.
44. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, Chang SF, Liao WS, Chen CH, Lee YT. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102: 933-941.
45. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, Ha KS, Han JA, Chung HT, Kwon YG, Kim YM. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem. 2005;280:5781-5788.
46. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteiny-lation on human high-density lipoproteins: a correlation with paraoxonase activity. Metab Clin Exp. 2003;52:146-151.
47. Barbato JC, Catanescu O, Murray K, DiBello PM, Jacobsen DW. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol. 2007;27:49-54.
48. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within! Arterioscler Thromb Vasc Biol. 2007;27:8-11.
49. Zhou J, Werstuck GH, Lhotak S, Shi YY, Tedesco V, Trigatti B, Dickhout J, Majors AK, DiBello PM, Jacobsen DW, Austin RC. Hyper-homocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice. FASEB J. 2008;22: 2569-2578.
50. Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS, Moller J, Ritskes-Hoitinga M, Falk E, Dayal S, Lentz SR, Austin RC. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation. 2004;110:207-213.
51. Nyblom HK, Sargsyan E, Bergsten P. AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels. J Mol Endocrinol. 2008;41:187-194.